Individualized Medicine

• 

  Subject Areas on Research

  • 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. 
  • 2020 visions. 
  • A "shocking" new code status. 
  • A Bayesian approach to subgroup identification. 
  • A General Cutoff Level Combined With Personalized Dynamic Change of Serum Carcinoembryonic Antigen Can Suggest Timely Use of FDG PET for Early Detection of Recurrent Colorectal Cancer. 
  • A Global Collaborative to Advance Genomic Medicine. 
  • A framework for self-experimentation in personalized health. 
  • A generalized estimator of the attributable benefit of an optimal treatment regime. 
  • A hub for bench-to-bedside pharmacogenomic-based research. 
  • A logic model for precision medicine implementation informed by stakeholder views and implementation science. 
  • A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. 
  • A nonsurgical permanent contraception stakeholder advisory committee: FHI 360's experience. 
  • A note from the editors. 
  • A personalized paradigm in the treatment of platinum-resistant ovarian cancer - A cost utility analysis of genomic-based versus cytotoxic therapy. 
  • A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. 
  • A public resource facilitating clinical use of genomes. 
  • A rationalized approach to the treatment of patients infected with hepatitis B. 
  • A roadmap for precision medicine in the epilepsies. 
  • A view from the side-line. 
  • Academic medical centers: ripe for rapid-learning personalized health care. 
  • Accelerating anticancer drug development - opportunities and trade-offs. 
  • Adapting clinical trial design to maintain meaningful outcomes during a multicenter asthma trial in the precision medicine era. 
  • Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. 
  • Adjusting for misclassification in a stratified biomarker clinical trial. 
  • Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors. 
  • Affiliate network members as force amplifiers of genomic medicine research. 
  • Aligning incentives to fulfil the promise of personalised medicine. 
  • American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. 
  • American Society of Clinical Oncology 2013 top five list in oncology. 
  • American society of clinical oncology statement: toward individualized care for patients with advanced cancer. 
  • An imprecise path to precision medicine. 
  • An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions. 
  • An informatics research agenda to support precision medicine: seven key areas. 
  • An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. 
  • An outlook on precision surgery. 
  • Analysis of Factors Associated With In-hospital Mortality in Lung Cancer Chemotherapy Patients With Neutropenia. 
  • Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. 
  • Antiplatelet therapy beyond 2012: role of personalized medicine. 
  • Antipsychotics and dementia: where do we go from here? 
  • Artificial intelligence framework for simulating clinical decision-making: a Markov decision process approach. 
  • Assessing conscientious personality in primary care: an opportunity for prevention and health promotion. 
  • Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting. 
  • Assessing the Effect of Personalized Diabetes Risk Assessments During Ophthalmologic Visits on Glycemic Control: A Randomized Clinical Trial. 
  • Author's Reply. 
  • Auxiliary variable-enriched biomarker-stratified design. 
  • Battlefield to Bedside: Bringing Precision Medicine to Surgical Care. 
  • Biobanking for Metabolomics and Lipidomics in Precision Medicine. 
  • Biomarker science: on a theme of personalized medicine. 
  • Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. 
  • Biomarkers as drug development tools: discovery, validation, qualification and use. 
  • Biomarkers for equine joint injury and osteoarthritis. 
  • Biospecimen Sharing Among Hispanic Women in a Safety-Net Clinic: Implications for the Precision Medicine Initiative. 
  • Biospecimens and biorepositories for the community pathologist. 
  • Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy. 
  • Building evidence and measuring clinical outcomes for genomic medicine. 
  • Cancer 2015: a longitudinal whole-of-system study of genomic cancer medicine. 
  • Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. 
  • Cardiovascular Research and the National Academy of Medicine: Advancing Progress in Science and Medicine: Part 2: What We Do. 
  • Cardiovascular precision medicine: hope or hype? 
  • Cell plasticity in lung injury and repair: report from an NHLBI workshop, April 19-20, 2010. 
  • Challenges and strategies for implementing genomic services in diverse settings: experiences from the Implementing GeNomics In pracTicE (IGNITE) network. 
  • Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine. 
  • Clinical Impact of Pharmacogenetic-Guided Treatment for Patients Exhibiting Neuropsychiatric Disorders: A Randomized Controlled Trial. 
  • Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. 
  • Clinical cancer informatics: creating pathways for personalized medicine and rapid learning cancer care from the guest editors. 
  • Clinical genomic testing: getting it right. 
  • Clinical phenotyping in selected national networks: demonstrating the need for high-throughput, portable, and computational methods. 
  • Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey. 
  • Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. 
  • Comment on “Comparison of patient specific dose metrics between chest radiography, tomosynthesis, and CT for adult patients of wide ranging body habitus” [Med. Phys. 41(2), 023901 (12pp.) (2014)]. 
  • Commentary: Personalized health planning and the Patient Protection and Affordable Care Act: an opportunity for academic medicine to lead health care reform. 
  • Comparative effectiveness research and demonstrating clinical utility for molecular diagnostic tests. 
  • Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond. 
  • Comparison of patient specific dose metrics between chest radiography, tomosynthesis, and CT for adult patients of wide ranging body habitus. 
  • Complexity of Delivering Precision Medicine: Opportunities and Challenges. 
  • Comprehensive genomic profiling of relapsed and metastatic adenoid cystic carcinomas by next-generation sequencing reveals potential new routes to targeted therapies. 
  • Computational approach to radiogenomics of breast cancer: Luminal A and luminal B molecular subtypes are associated with imaging features on routine breast MRI extracted using computer vision algorithms. 
  • Considerations for the impact of personal genome information: a study of genomic profiling among genetics and genomics professionals. 
  • Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. 
  • Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. 
  • Creating and parameterizing patient-specific deep brain stimulation pathway-activation models using the hyperdirect pathway as an example. 
  • Current Opportunities and Future Vision of Precision Medicine in Radiation Oncology. 
  • Cystic fibrosis: a model for personalized genetic medicine. 
  • Design and inference for cancer biomarker study with an outcome and auxiliary-dependent subsampling. 
  • Designing a broad-spectrum integrative approach for cancer prevention and treatment. 
  • Developing a common framework for evaluating the implementation of genomic medicine interventions in clinical care: the IGNITE Network's Common Measures Working Group. 
  • Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer. 
  • Development of a Comprehensive, Nonsurgical Joint Health Program for People With Osteoarthritis: A Case Report. 
  • Digital pathology in nephrology clinical trials, research, and pathology practice. 
  • Drug development in the era of precision medicine. 
  • Dynamic treatment regimes, past, present, and future: A conversation with experts. 
  • EUS-FNA and needle echogenicity in the age of personalized medicine. 
  • Educating future providers of personalized medicine. 
  • Effectiveness of a Personalized Brain-Computer Interface System for Cognitive Training in Healthy Elderly: A Randomized Controlled Trial. 
  • Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings. 
  • Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study. 
  • Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. 
  • Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials. 
  • Estimating Preferences for Complex Health Technologies: Lessons Learned and Implications for Personalized Medicine. 
  • Evidence-Based versus Personalized Medicine in Pediatric Urology: The Evidence Supports Evidence-Based Medicine. 
  • Extracellular Vesicles: A Brief Overview and Its Role in Precision Medicine. 
  • Finding the right balance between precision medicine and personalized care. 
  • Five-year downstream outcomes following prostate-specific antigen screening in older men. 
  • Functional assay to guide precision radiotherapy by assessing individual patient radiosensitivity. 
  • Future of Personalized Cardiovascular Medicine: JACC State-of-the-Art Review. 
  • GUCY2C molecular staging personalizes colorectal cancer patient management. 
  • Genetic determinants of renal transplant outcome: where do we stand? 
  • Genetic polymorphisms modify bladder cancer recurrence and survival in a USA population-based prognostic study. 
  • Genic intolerance to functional variation and the interpretation of personal genomes. 
  • Genome Engineering for Personalized Arthritis Therapeutics. 
  • Genome technologies and personalized dental medicine. 
  • Genomic and personalized medicine: foundations and applications. 
  • Genomic stratification for the treatment of lymphomas. 
  • Genomic translational research: Paving the way to individualized cardiac functional analyses and personalized cardiology. 
  • Genotyping Array Design and Data Quality Control in the Million Veteran Program. 
  • Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. 
  • Global implementation of genomic medicine: We are not alone. 
  • Global position paper on cardiovascular regenerative medicine. 
  • HGV2011: personalized genomic medicine meets the incidentalome. 
  • Harmonizing Clinical Sequencing and Interpretation for the eMERGE III Network. 
  • Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee. 
  • High-risk multiple myeloma: does it still exist? 
  • Horizon Scan Of Clinical Laboratories Offering Pharmacogenetic Testing. 
  • How Advances in Imaging Will Affect Precision Radiation Oncology. 
  • Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization. 
  • IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. 
  • ISPAD Clinical Practice Consensus Guidelines 2014. Microvascular and macrovascular complications in children and adolescents. 
  • Impact of Rare and Common Genetic Variants on Diabetes Diagnosis by Hemoglobin A1c in Multi-Ancestry Cohorts: The Trans-Omics for Precision Medicine Program. 
  • Impact of direct-to-consumer predictive genomic testing on risk perception and worry among patients receiving routine care in a preventive health clinic. 
  • Implementing family health history risk stratification in primary care: impact of guideline criteria on populations and resource demand. 
  • Implementing genome-driven personalized cardiology in clinical practice. 
  • Improving Clinical Outcomes in the Era of Information Ubiquity. 
  • Improving the management of dyspnea in the community using rapid learning approaches. 
  • Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics. 
  • Individualized Homeopathy: A Consideration of Its Relationship to Psychotherapy. 
  • Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease. 
  • Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial. 
  • Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy. 
  • Individualized therapy for persistent asthma in young children. 
  • Individualizing duration of antibiotic therapy in community-acquired pneumonia. 
  • Individualizing treatment decisions for older adults with hematologic malignancies. 
  • Inference on treatment effects for targeted clinical trials under enrichment design. 
  • Inflammation (or synovitis)-driven osteoarthritis: an opportunity for personalizing prognosis and treatment? 
  • Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors. 
  • Integrated precision medicine: the role of electronic health records in delivering personalized treatment. 
  • Integration of Personalized Health Planning and Shared Medical Appointments for Patients with Type 2 Diabetes Mellitus. 
  • Integrative molecular profiling of routine clinical prostate cancer specimens. 
  • Interdisciplinary Models for Research and Clinical Endeavors in Genomic Medicine: A Scientific Statement From the American Heart Association. 
  • Introducing personalized health for the family: the experience of a single hospital system. 
  • Introduction to the 58th Annual Thomas L. Petty Aspen Lung Conference: Asthma 2015: Mechanisms to Personalized Medicine. 
  • In vitro generation of renal tubular epithelial cells from fibroblasts: implications for precision and regenerative medicine in nephrology. 
  • Logistical Challenges Associated With Implementing Precision Medicine-Reply. 
  • Looking to the future of research in pediatric anxiety disorders. 
  • Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All? 
  • Making Clinical Practice Guidelines Pragmatic: How Big Data and Real World Evidence Can Close the Gap. 
  • Making Personalized Health Care Even More Personalized: Insights From Activities of the IOM Genomics Roundtable. 
  • Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. 
  • Managing Increased Accessibility to Pharmacogenomic Data. 
  • Medical genomics: Gather and use genetic data in health care. 
  • Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine. 
  • Metabolomics reveals intratumor heterogeneity - Implications for precision medicine. 
  • Methionine metabolism in health and cancer: a nexus of diet and precision medicine. 
  • Mind-mapping for lung cancer: towards a personalized therapeutics approach. 
  • Mobile health technology for personalized primary care medicine. 
  • Molecular Genomic Testing for Breast Cancer: Utility for Surgeons. 
  • Molecular markers for incidence, prognosis, and response to therapy. 
  • Molecular testing in colorectal cancer: diagnosis of Lynch syndrome and personalized cancer medicine. 
  • Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges. 
  • Neuropsychiatric genomics in precision medicine: diagnostics, gene discovery, and translation. 
  • Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic? 
  • Nursing implications of personalized and precision medicine. 
  • ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY. 
  • Offering individual genetic research results: context matters. 
  • On Enrichment Strategies for Biomarker Stratified Clinical Trials. 
  • Only connect: personal genomics and the future of American medicine. 
  • Open Humans: A platform for participant-centered research and personal data exploration. 
  • Opportunities for the Cardiovascular Community in the Precision Medicine Initiative. 
  • Opportunities to implement a sustainable genomic medicine program: lessons learned from the IGNITE Network. 
  • Opportunities, resources, and techniques for implementing genomics in clinical care. 
  • Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. 
  • Osteoarthritis--a case for personalized health care? 
  • Outcome of Whole Exome Sequencing for Diagnostic Odyssey Cases of an Individualized Medicine Clinic: The Mayo Clinic Experience. 
  • Overcoming barriers in the implementation of personalized medicine into clinical practice. 
  • Partial Meal Replacement Plan and Quality of the Diet at 1 Year: Action for Health in Diabetes (Look AHEAD) Trial. 
  • Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. 
  • Patient-Centered Communication for Discussing Oncotype DX Testing. 
  • Patient-specific quantification of image quality: An automated method for measuring spatial resolution in clinical CT images. 
  • Patient-specific radiation dose and cancer risk estimation in CT: part I. development and validation of a Monte Carlo program. 
  • Patient-specific radiation dose and cancer risk estimation in CT: part II. Application to patients. 
  • Perceived functioning has ethnic-specific associations in systemic sclerosis: another dimension of personalized medicine. 
  • Perioperative fluid and hemodynamic management within an enhanced recovery pathway. 
  • Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation. 
  • Personalized analgesic management for cesarean delivery. 
  • Personalized and targeted therapy of esophageal squamous cell carcinoma: an update. 
  • Personalized diagnostics and biosensors: a review of the biology and technology needed for personalized medicine. 
  • Personalized health care in 2013: a status report on the impact of genomics. 
  • Personalized health care: from theory to practice. 
  • Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. 
  • Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. 
  • Personalized medicine and human genetic diversity. 
  • Personalized medicine in women's obesity prevention and treatment: implications for research, policy and practice. 
  • Personalized medicine: progress and promise. 
  • Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. 
  • Personalized targeted therapy for esophageal squamous cell carcinoma. 
  • Personalized treatment in patients with colorectal liver metastases. 
  • Personalized treatment of lung cancer. 
  • Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. 
  • Pharmacogenetic guidance for antiplatelet treatment. 
  • Pharmacogenomics courses in pharmacy school curricula. 
  • Pharmacogenomics for personalized pain medicine. 
  • Pharmacogenomics in childhood rheumatic disorders: a foundation for future individualized therapy. 
  • Pharmacogenomics in pediatric rheumatology. 
  • Pharmacogenomics of adverse drug reactions: implementing personalized medicine. 
  • PhenX RISING: real world implementation and sharing of PhenX measures. 
  • PhenoDis: a comprehensive database for phenotypic characterization of rare cardiac diseases. 
  • Phenomics and the interpretation of personal genomes. 
  • Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. 
  • Physiologic goal-directed therapy in the perioperative period: the volume prescription for high-risk patients. 
  • Platelet monitoring for PCI: is it really necessary? 
  • Platelet-Mediated Thrombosis: From Bench to Bedside. 
  • Population genomics in South East Asia captures unexpectedly high carrier frequency for treatable inherited disorders. 
  • Potential of whole-genome sequencing for determining risk and personalizing therapy: focus on AML. 
  • Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer. 
  • Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests. 
  • Precision Medicine Approaches When Prostate Cancer Akts Up. 
  • Precision Medicine for CRC Patients in the Veteran Population: State-of-the-Art, Challenges and Research Directions. 
  • Precision Medicine for Critical Illness and Injury. 
  • Precision Medicine for Heart Failure: Lessons From Oncology. 
  • Precision Medicine: From Science To Value. 
  • Precision and predictive medicine: lessons learned from our oncology colleagues. 
  • Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors. 
  • Precision diagnosis: a view of the clinical decision support systems (CDSS) landscape through the lens of critical care. 
  • Precision health: Advancing symptom and self-management science. 
  • Precision medicine comes of age in nephrology: identification of novel biomarkers and therapeutic targets for chronic kidney disease. 
  • Precision medicine for psychopharmacology: a general introduction. 
  • Precision medicine in addiction research: where has the time gone? 
  • Predicting critical illness mortality and personalizing therapy: moving to multi-dimensional data. 
  • Predicting risk of diabetic retinopathy from retinal vessel analysis: personalized medicine in transition. 
  • Predictors of consent to pharmacogenomics testing in the IDEAL study. 
  • Preserving an integrated view of informatics. 
  • Providing personalized prognostic information for adult leukemia survivors. 
  • Quantitative analysis of the factors which affect the interpatient organ-at-risk dose sparing variation in IMRT plans. 
  • Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer. 
  • Radiogenomics: what it is and why it is important. 
  • Randomised placebo-controlled trials of individualised homeopathic treatment: systematic review and meta-analysis. 
  • Rapid-learning system for cancer care. 
  • Rationale for hypoxia assessment and amelioration for precision therapy and immunotherapy studies. 
  • Realizing the Full Potential of Precision Medicine in Health and Health Care. 
  • Realizing the opportunities of genomics in health care. 
  • Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: Design of and rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease Study. 
  • Refocusing the war on cancer: the critical role of personalized treatment. 
  • Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. 
  • Resilience in Clinical Care: Getting a Grip on the Recovery Potential of Older Adults. 
  • Resistance to antiplatelet drugs: what progress has been made? 
  • Response to: 'Lack of standardization of ANA and implications for drug development and precision medicine' by Mahler. 
  • Review of the biology of bleeding and clotting in the surgical patient. 
  • Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors. 
  • Sleep Pharmacogenetics: The Promise of Precision Medicine. 
  • Start me up: ways to encourage sharing of genomic information with research participants. 
  • Statistical issues and advances in cancer precision medicine research. 
  • Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine. 
  • Survey of US public attitudes toward pharmacogenetic testing. 
  • Systematic Molecular Phenotyping: A Path Toward Precision Emergency Medicine? 
  • Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach? 
  • Tailoring nutrition therapy to illness and recovery. 
  • Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type? 
  • Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer. 
  • Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. 
  • The Adolescent and Young Adult with Cancer: A Developmental Life Course Perspective. 
  • The Call for Precision Health Trials in Older Adults: One Size Does Not Fit All. 
  • The Genomic Medicine Integrative Research Framework: A Conceptual Framework for Conducting Genomic Medicine Research. 
  • The IGNITE network: a model for genomic medicine implementation and research. 
  • The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. 
  • The Uniformed Services University's Surgical Critical Care Initiative (SC2i): Bringing Precision Medicine to the Critically Ill. 
  • The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. 
  • The current clinical value of the DCIS Score. 
  • The economics of new drugs: can we afford to make progress in a common disease? 
  • The imperative of overcoming barriers to the conduct of large, simple trials. 
  • The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors. 
  • The next 10 years in personalized medicine in cardiology. 
  • The oral microbiome in health and disease and the potential impact on personalized dental medicine. 
  • The pharmacogenetics of antiplatelet agents: towards personalized therapy? 
  • The predictive capacity of personal genome sequencing. 
  • The rise of genomic profiling in ovarian cancer. 
  • The ultimate personalised medicine. 
  • The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient. 
  • Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. 
  • Toward Tailored Interventions: Sympathetic and Parasympathetic Functioning Predicts Responses to an Intervention for Conduct Problems Delivered in Two Formats. 
  • Toward a Shared Vision for Cancer Genomic Data. 
  • Towards precision medicine: Accurate predictive modeling of infectious complications in combat casualties. 
  • Towards precision prevention: Technologies for identifying healthy individuals with high risk of disease. 
  • Toxin-based targeted therapy for malignant brain tumors. 
  • Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action. 
  • Translational Bioinformatics: Past, Present, and Future. 
  • Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. 
  • Twenty-First Century Cures Act. 
  • Unequal representation of genetic variation across ancestry groups creates healthcare inequality in the application of precision medicine. 
  • Update on Surgical Management of Small Bowel Neuroendocrine Tumors. 
  • Update: Acute coronary syndromes (V). Personalized antiplatelet therapy. 
  • Using decision lists to construct interpretable and parsimonious treatment regimes. 
  • Using evidence-based algorithms to improve clinical decision making: the case of a first-time anterior shoulder dislocation. 
  • Using mathematical models to understand metabolism, genes, and disease. 
  • Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy. 
  • Utilizing Precision Medicine to Estimate Timing for Surgical Closure of Traumatic Extremity Wounds. 
  • Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. 
  • Validation of a host response test to distinguish bacterial and viral respiratory infection. 
  • Value of Personalized Medicine. 
  • Ways of knowing in precision health. 
  • What will it take to implement genomics in practice? Lessons from the IGNITE Network. 
  • What's New in Genetic Testing for Cancer Susceptibility? 
  • Who gains clinical benefit from using insulin pump therapy? A qualitative study of the perceptions and views of health professionals involved in the Relative Effectiveness of Pumps over MDI and Structured Education (REPOSE) trial. 
  • Will Precision Medicine Move Us beyond Race? 
  • [Personalized therapy of lung cancer - current standard and future challenges]. 
  • [Variation of mortality risk among cancer patients and individualized therapy]. 
• 

  Keywords of People

  • Bitting, Rhonda L, Instructor in the Department of Medicine, Medicine, Medical Oncology
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • Halabi, Susan, Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Orlando, Lori Ann, Associate Professor of Medicine, Medicine, General Internal Medicine
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Shaw, Ryan, Associate Professor in the School of Nursing, Duke Innovation & Entrepreneurship
  • Tenenbaum, Jessica Dale, Assistant Professor of Biostatistics & Bioinformatics, Duke Science & Society